Shin Nippon Biomedical Laboratories, Ltd. to Expand Research and Development Facilities! Location Agreement Signed with Kagoshima City!
Shin Nippon Biomedical Laboratories signs a location agreement with Kagoshima City to expand its research and development facilities, aiming for business growth.
📋 Article Processing Timeline
- 📰 Published: March 30, 2026 at 22:41
- 🔍 Collected: March 30, 2026 at 22:56 (14 min after Published)
- 🤖 AI Analyzed: April 16, 2026 at 04:33 (389h 37m after Collected)
■ Location Agreement Ceremony with Shin Nippon Biomedical Laboratories, Ltd.
Date: March 30, Reiwa 8 (2026) (Monday) 11:00 AM - 11:20 AM
Location: Special Conference Room, 2nd Floor, Main Building, Kagoshima City Hall
Attendees: Company… Ryoichi Nagata, Chairman and President, Shin Nippon Biomedical Laboratories, Ltd.
Kagoshima City… Takaaki Shimotsuru, Mayor
Witness… Takashi Kitamura, Director, Commerce, Labor and Fisheries Department, Kagoshima Prefecture
(Photo) Scene from the Location Agreement Ceremony
■ Overview of Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. was founded in Kagoshima City in September 1957 as Japan's first contract research organization for pharmaceutical development. Since then, the company has been developing its core business as a CRO (Contract Research Organization) that supports pharmaceutical development, including non-clinical studies¹, clinical trials², and new drug application procedures, for pharmaceutical and biotechnology companies.
This expansion of research facilities is due to the high evaluation of its rapid and stable non-clinical study implementation system, which has led to the acquisition of Preferred Vendor agreements (priority contract agreements) with major European and American pharmaceutical companies. Further expansion of orders is anticipated, necessitating this facility expansion. It is expected that this will promote the development of new drugs from Kagoshima to the world, and significantly contribute to job creation and regional revitalization in the city.
¹ Non-clinical studies: Studies to confirm the efficacy and safety of drugs under development before clinical trials².
² Clinical trials: Studies to confirm the efficacy and safety of drugs in humans.
³ CRO (Contract Research Organization): An organization that undertakes the operation and management of non-clinical studies¹ and clinical trials² from pharmaceutical companies, etc., and supports (acts on behalf of) drug development.
■ Overview of the Expanded Research and Development Facility Plan
(1) Facility Name: NHP Experimental Facility EU Experimental Building
(2) Location: Part of 2642-1 Miyano-ura Town, Kagoshima City, etc.
(3) Land Area: 11,384.98 m² (3,443.95 tsubo)
(4) Building Area: 11,765.18 m² (3,558.96 tsubo)
(5) Scheduled Start of Operations: November, Reiwa 9 (2027)
(6) Planned Number of Employees: 1,175 employees at Kagoshima Headquarters (including 85 new hires) *As of the 5th year
(7) Business Content: Non-clinical CRO business
■ Related URL
Kagoshima City fully supports companies expanding in the fields of research and development facilities, information and communications, business processing centers/call centers, design and content production, and manufacturing!
【Contact Information】
Kagoshima City Industrial Creation Division, Business Location Section
11-1 Yamashita-cho, Kagoshima City, Kagoshima Prefecture, 892-8677
TEL: 099-216-1314
FAX: 099-216-1303
E-mail: yuuchi@city.kagoshima.lg.jp
FAQ
What is Shin Nippon Biomedical Laboratories, Ltd. (SNBL)?
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization (CRO) founded in Kagoshima City in 1957. It primarily supports pharmaceutical development by conducting non-clinical and clinical studies for pharmaceutical and biotechnology companies.
Why is SNBL expanding its research facilities?
The expansion is driven by increased demand from major European and American pharmaceutical companies, leading to the acquisition of preferred vendor agreements. The company anticipates further order growth and needs to increase its capacity.
What is the planned new facility called and where will it be located?
The new facility will be named the 'NHP Experimental Facility EU Experimental Building' and will be located in part of Miyano-ura Town, Kagoshima City.
When is the new facility expected to start operations?
The new facility is scheduled to begin operations in November 2027 (Reiwa 9).
What is the expected impact of this expansion on Kagoshima City?
The expansion is expected to promote new drug development globally from Kagoshima, create new jobs (85 new hires planned), and contribute significantly to the revitalization of the local economy.
What is a CRO?
CRO stands for Contract Research Organization. It is an organization that undertakes the operation and management of non-clinical and clinical studies for pharmaceutical companies, supporting their drug development process.